Fri, Feb 10|
STARS Rehab, suite 3
FINALLY, a reliable skin-based test that helps clinicians diagnose Parkinson’s disease and other neurological disorders
Backed by a decade of science and research, the Syn-One Test® is the first commercially available test of its kind. A simple skin biopsy performed in a physician’s office, provides pathological proof of a synucleinopathy, a family of neurological disorders that includes Parkinson's Disease.
Time & Location
Feb 10, 3:30 PM – 4:30 PM
STARS Rehab, suite 3, 4320 A1A S #3, St. Augustine, FL 32080, USA
About the event
Backed by a decade of science and research, the Syn-One Test® is the first commercially available test of its kind. Through a simple skin biopsy procedure performed in a physician’s office, the test provides pathological proof of a synucleinopathy, a family of neurological disorders that includes Parkinson’s disease and dementia with Lewy bodies.
The Syn-One Test can effectively detect and visualize the abnormal or “misfolded” form of the alpha-synuclein protein in the nerves of your skin. Everyone has the useful form of alpha-synuclein in their bodies, but for patients who have a disease like Parkinson’s, the protein misfolds and clumps together over time, causing adverse effects in the nervous system. Because there are several different health conditions that may give the appearance of Parkinson’s disease but are actually different disorders, the Syn-One Test allows your physician to have more objective and specific proof to make an accurate diagnosis as early in the disease process as possible. We invite you to learn more about this new and important diagnostic technology!
Matt Markelon will be our speaker and he represents CND Life Sciences.